Ovarian Cancer Serum
Ovarian Cancer Serum — serum from clinically confirmed ovarian cancer donors, frozen within 24 hours. Ideal for CA-125 and HE4 immunoassay development, multi-marker panel work, early-detection biomarker discovery, and proteomic profiling. Histological subtype, stage, BRCA status, and treatment history available for stratification.
Ovarian Cancer Serum for Oncology Biomarker Research
Our Ovarian Cancer Serum is sourced from IRB-consented donors clinically diagnosed with ovarian cancer. Each sample is processed and frozen within 24 hours of collection to preserve tumour markers, cytokines, and other circulating proteins. Serum is acellular, so this product supports soluble-analyte work rather than cell-based assays.
Ovarian Cancer Biology and Why Serum
Ovarian cancer is a neoplastic disease, and one where circulating protein markers have a long-established role in clinical monitoring and in early-detection research:
- High-grade serous carcinoma is the dominant histotype, and evidence indicates that many of these tumours originate in the distal fallopian tube epithelium rather than the ovarian surface, arising through serous tubal intraepithelial carcinoma precursors
- Near-universal TP53 mutation characterises high-grade serous disease, alongside widespread copy-number instability rather than a small set of recurrent driver point mutations
- Homologous recombination deficiency — through germline or somatic BRCA1/BRCA2 mutation and other repair defects — defines the subgroup sensitive to platinum chemotherapy and to PARP inhibitors
- CA-125 is the established serum marker, used clinically for treatment response and recurrence monitoring; HE4 and the ROMA algorithm are used in the assessment of adnexal masses. None of these are adequate as standalone screening tests, which is why serum biomarker discovery remains active
- Late-stage presentation is the norm, because early disease is largely asymptomatic — the central problem that early-detection biomarker research is trying to solve
- Why serum: serum is the reference matrix for CA-125 and HE4 immunoassays, supports multiplex protein panels, proteomics, and metabolomics, and yields high aliquot counts and serial timepoints from a single donor
Donor Stratification Available
- Histological subtype: high-grade serous, low-grade serous, endometrioid, clear cell, or mucinous
- Stage at collection, from early-stage to advanced or recurrent disease
- BRCA1/BRCA2 mutation status where clinically tested
- Treatment status: treatment-naive, on platinum-based chemotherapy, on PARP inhibitor maintenance, or post-treatment surveillance
- Platinum sensitivity or resistance category where documented
- CA-125 results where clinically measured; age, menopausal status, and race/ethnicity
- Matched healthy female controls and benign gynaecological comparators available
Product Features
- Collected from clinically confirmed ovarian cancer donors
- Processed and frozen within 24 hours of collection
- Research Use Only (RUO)
- Standard and custom aliquot volumes available
- Serial collections from the same donor available on request
- IRB-approved protocols with documented consent
De-identified Donor Data
- Diagnosis confirmation, with histological subtype and stage where documented
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Treatment history, tumour marker results, and family history available on request
Applications
- CA-125 and HE4 immunoassay development, validation, and comparison
- Multi-marker panel and algorithm development for adnexal mass assessment
- Early-detection biomarker discovery
- Serum proteomic, glycoproteomic, and metabolomic profiling
- Treatment response and recurrence monitoring biomarker research
- Platinum resistance and PARP inhibitor response biomarker studies
- Circulating cytokine, angiogenic factor, and inflammatory mediator profiling
- Case-control and longitudinal study design with matched controls
Other Ovarian Cancer Specimen Types
- Ovarian Cancer Plasma — anticoagulated matrix, preferred for circulating tumour DNA work
- Ovarian Cancer Whole Blood — fresh, for germline testing and same-day cellular assays
- Ovarian Cancer PBMC — cryopreserved cells for tumour immunology
- Solid Tumor Cancer PBMC — for pan-tumour comparisons
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering and Customization
Ovarian cancer serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For healthy-donor controls and the full specimen range, see our human serum collection.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.